As we step into 2024, the realm of market access undergoes dynamic shifts influenced by technological advancements, policy changes, and evolving consumer behaviors. There are the usual suspects like evolving provider models, the continued transition to value-based care, and pharma and biotech companies’ increased investment in “access,” but there are two trends that are at the top of the “what we’re watching” list for 2024.
Featured Posts
PERIOD., a global youth-powered non-profit, launched the typeface, Sans Period, to provide crucial period education for kids who may no longer get it in school.
Many telehealth policies expanded during the pandemic have been extended through December 31, 2024. Beyond that, policymakers will need to make hard decisions or continue with temporary extensions. Either way, a range of changes in telehealth are coming and will impact reimbursement policies, technology infrastructure, privacy, provider and patient/member adoption, and economic factors.
A federal judge on Monday dismissed a lawsuit by a major pharmaceutical industry trade association challenging a new program that allows Medicare to negotiate prices with drug companies for selected costly drugs.
The combined businesses unlock significant opportunity for clients with strategic, differentiated clinical trial recruitment, engagement and retention approaches, along with compelling creative solutions and best-in-class analytics.
Brannon Cashion, president of specialty services at Fingerpaint Group, shares with Med Ad News how intentional integration and collaboration are key factors in building a successful organization, along with the role that market access and medical communications play.
Global President of Fingerpaint Group Bill McEllen speaks with Med Ad News about how the agency’s entrepreneurial spirit and its passionate people foster a culture that inspires creativity, and more.
With over two decades of experience in producing impactful campaigns across consumer, health & wellness, and pharmaceutical brands, Renata Maia will oversee the creative product across all Ogilvy Health offerings including brand development, strategy, experience and innovation, PR and influence, medical education, and market access.
This acquisition has more than doubled Real Chemistry’s present medical team, empowering both new and current clients to have access to unparalleled expertise in HCP engagement and communications.